But the impact of proton pump inhibitors (PPIs) on liver disease progression has been unknown.
Researchers have found in a nation-wide cohort study that PPI use was associated with an increased risk of fatty liver disease compared with non‐use of PPIs. The Clinicians should therefore consider fatty liver as a potential risk when prescribing PPIs. The study has been published in the journal Gastroenterology.
The Proton‐pump inhibitor (PPI)‐induced hypochondria can change the composition of the gut microbiota, inducing overgrowth of small bowel bacteria, which has been suggested to promote the development of fatty liver disease through the gut‐liver axis.This suggests that changes in gut microbiota can affect the progression of liver disease.
The researchers conducted a retrospective cohort study to investigate the association between Proton‐pump inhibitor use and the risk of fatty liver disease.
They used the Korean National Health Insurance Service‐National Sample Cohort, a nationwide population‐based representative sample, from January 1, 2002, to December 31, 2015. PPI use was identified from treatment claims and considered as a time‐varying variable.
They found that-
During 1,463,556 person‐years of follow‐up, 75,727 patients had at least one PPI prescription and 3,735 patients developed fatty liver disease.
The hazard ratio (HR) for fatty liver disease comparing PPI users to non‐PPI users was 1.68 [95% confidence interval (CI), 1.61–1.75].
When adjusted for multiple confounders, including age, sex, body mass index, smoking, alcohol intake, exercise, income level, and comorbidities, the association was still significant (HR, 1.50; 95% CI, 1.44–1.57).
After considering the amounts of PPIs stratified by cumulative defined daily dose, the dose‐response effect was observed until 180 days.
Subgroup analysis also revealed that PPI use was correlated to an increased risk of fatty liver disease.
The researchers concluded that this current national wide cohort study suggests that Proton‐pump inhibitor use was associated with an increased risk of fatty liver disease compared with non‐use of PPIs. Clinicians should consider fatty liver as a potential risk when prescribing PPI.
For further reference log on to:
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd